Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

doi:10.1158/1078-0432.CCR-14-2821

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2015

Arena Sabrina, Bellosillo Beatriz, Siravegna Giulia, Martínez Alejandro, Cañadas Israel, Lazzari Luca, Ferruz Noelia, Russo Mariangela, Misale Sandra, González Iria, Iglesias Mar, Gavilan Elena, Corti Giorgio, Hobor Sebastijan, Crisafulli Giovanni, Salido Marta, Sánchez Juan, Dalmases Alba, Bellmunt Joaquim, De Fabritiis Gianni, Rovira Ana, Di Nicolantonio Federica, Albanell Joan, Bardelli Alberto, Montagut Clara

Abstract excerpt

PURPOSE: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signaling axis on the acquisition of resistance to cetuximab in patients and cellular models. EXPERIMENTAL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Extracellular Space

Share to Flow Cytometry

Share to Genes, erbB-1

Share to Real-Time Polymerase Chain Reaction

Source

Open in PubMed

Identifiers

PMID: 25623215
DOI: 10.1158/1078-0432.CCR-14-2821

Genes

EGFR
BRAF
KRAS
NRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.PMID 25623215Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSemantic proximity Read ↗

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Semantic proximity Read ↗

EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Semantic proximity Read ↗

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced ResistanceSemantic proximity Read ↗

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

Overcoming Resistance to Anti-EGFR Therapy in Colorectal CancerSemantic proximity Read ↗

Colorectal adenocarcinoma‐derived EGFR mutants are oncogenic and sensitive to EGFR‐targeted monoclonal antibodies, cetuximab and panitumumabSemantic proximity Read ↗

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.Semantic proximity Read ↗

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.